Basic Information
| LncRNA/CircRNA Name | lnc-DILC |
| Synonyms | TFDP1, DILC, DP1, DRTF1, Dp-1 |
| Region | GRCh38_13:113584721-113641470 |
| Ensemble | ENSG00000198176 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gallbladder cancer |
| ICD-0-3 | C23.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, etc. |
| Sample | GBC tissue,distant metastasis tissues,cholecystitis tissue, GBC cell lines SGC-996 and GBC-SD |
| Expression Pattern | up-regulated |
| Function Description | lnc-DILC is upregulated in gallbladder CSCs and GBC patients' tissues. Knockdown of lnc-DILC attenuates the self-renewal, tumorigenicity, proliferation and metastasis of gallbladder CSCs. Mechanistically, lnc-DILC promotes gallbladder CSCs expansion via Wnt/?-catenin pathway. Special Wnt/?-catenin inhibitor FH535 diminishes the discrepancy of self-renewal, growth and metastasis between lnc-DILC interference GBC cells and their control cells. In conclusion, lnc-DILC drives gallbladder CSCs self-renewal, tumorigenicity, proliferation and metastasis by activating Wnt/?-catenin signaling, and may therefore prove to be a potential therapeutic target for GBC patients. |
| Pubmed ID | 30716440 |
| Year | 2019 |
| Title | Long non-coding RNA DILC promotes the progression of gallbladder carcinoma. |
External Links
| Links for lnc-DILC | GenBank HGNC NONCODE |
| Links for gallbladder cancer | OMIM COSMIC |